The short version of Peptide content fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-23. Anything still debated is marked as such rather than presented as settled.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Acetylated heptapeptide form |
| Monoisotopic mass | 888.5 Da | Average mass about 889 Da |
| Appearance | White to off-white solid | Usually supplied as lyophilised powder |
| Solubility class | Highly water soluble | Also dissolves in aqueous buffers |
| Common synonyms | Tbeta4 fragment, thymosin beta-4 (17-23) | Refer to the same sequence |
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
The recommended safe daily dose of cannabidiol (CBD) is lowered by the Food Standards Agency, following concerns that long-term use might cause liver and other health problems. Downing Street announces that the UK will send surveillance aircraft and two Royal Navy ships to the eastern Mediterranean to support Israel. The Royal Mint unveils a new set of coins bearing the portrait of Charles III which will go into circulation at the end of the year. 13 October The Competition and Markets Authority approves Microsoft's £59bn takeover of Call of Duty-maker Activision Blizzard, the largest ever deal in video game history. The United Kingdom begins evacuating British citizens from Israel. The Metropolitan Police reports a "massive increase" in the number of antisemitic incidents in London between 30 September and 13 October, with 105 incidents and 75 offences, compared to 14 incidents and 12 offences during the same period of 2022. Sunak describes the increase as "disgusting". 14 October Michael Caine announces his retirement from acting at the age of 90, following the recent launch of his final film, The Great Escaper. Pro-Palestinian protests take place in cities across the UK, including London and Manchester, with police warning that anyone showing support for Hamas faces arrest. Red paint is sprayed over the BBC headquarters in central London. A pro-Palestinian group claims responsibility, citing the broadcaster's coverage of the Israel-Hamas war, but the Metropolitan police denies the incident is linked to a protest group and says no arrests have been made.
In chromatography, endcapping refers to the replacement of accessible silanol groups in a bonded stationary phase by trimethylsilyl groups. End-capped columns have much lower residual silanol group activity compared to non-endcapped columns. Endcapped columns show decreased retention for hydrogen bond acceptors, such as ionized bases, and increased retention for protonated bases.
Progeria (also Hutchinson–Gilford syndrome or Hutchinson–Gilford progeroid syndrome; HGPS) is a type of progeroid syndrome. A single gene mutation is responsible for causing progeria. The affected gene, known as lamin A (LMNA), makes a protein necessary for holding the cell nucleus together. When this gene mutates, an abnormal form of lamin A protein called progerin is produced. Progeroid syndromes are a group of diseases that cause individuals to age faster than usual. People born with progeria typically live until their mid- to late-teens or early twenties. Severe cardiovascular complications usually develop by puberty, later on resulting in death.
== See also == Capillary electrophoresis–mass spectrometry Ion-mobility spectrometry–mass spectrometry Liquid chromatography–mass spectrometry Prolate trochoidal mass spectrometer Pyrolysis–gas chromatography–mass spectrometry
== Early life == Flay was born on December 10, 1964, in New York City, to Bill and Dorothy Barbara (McGuirk) Flay. He was raised on the Upper East Side of Manhattan. He is a fourth-generation Irish American and was raised Catholic, attending denominational schools. At age 8, Flay asked for an Easy-Bake Oven for Christmas. His father thought that a G.I. Joe would be more appropriate. Despite his father's objections, he received them both.
Sources: en.wikipedia.org
{\displaystyle {\begin{array}{lll}M({\ce {He}})&=4.002602(2)\times M_{\mathrm {u} }&=4.002602(2){\text{ g/mol}}\\M({\ce {Ne}})&=20.1797(6)\times M_{\mathrm {u} }&=20.1797(6){\text{ g/mol}}\\M({\ce {Fe}})&=55.845(2)\times M_{\mathrm {u} }&=55.845(2){\text{ g/mol}}\\M({\ce {Cu}})&=63.546(3)\times M_{\mathrm {u} }&=63.546(3){\text{ g/mol}}\\M({\ce {Ag}})&=107.8682(2)\times M_{\mathrm {u} }&=107.8682(2){\text{ g/mol}}\end{array}}}
Whitney Halberstram (Max Minghella) is the enigmatic co-founder and CFO of payment processing startup Tender, which he launches with college friend Jonah Atterbury. An American who claims to have grown up in poverty, Whitney frequently alters details about his background depending on his audience. He pivots Tender away from pornography and gambling clients toward banking, forcing Jonah out and installing himself as interim CEO. Whitney has a one-night stand with Harper and befriends Yasmin, who introduces him to Labour MP Jennifer Bevan for regulatory leverage in exchange for securing her husband Henry Muck a role at Tender. Whitney appoints Henry CEO to leverage his aristocratic connections and develops a sexual fixation on him. After learning Harper is shorting Tender and working with journalist James Dycker to investigate its African operations, Whitney and Yasmin move to discredit Dycker in print; Whitney then promotes Yasmin to head of communications. After Harper publicly reveals that Tender falsified profits in Africa, the company’s stock drops sharply. Whitney is shown to be under pressure from Russian intelligence interests using Tender to collect UK consumer data. He persuades EMEA CFO Tony Day not to act as a whistleblower and proposes a hostile takeover of Pierpoint to delay scrutiny from auditors, falsely claiming he already owns a stake. He travels to New York with Henry for Pierpoint’s AGM but later attempts to flee, having secured a fake Lithuanian passport and hired a Japanese jōhatsu firm to facilitate his disappearance.
== Controversy == The 2014 summary policy statement of the American Academy of Pediatrics (AAP) makes no specific mention of bottle feeding, but makes clear that "[b]reastfeeding and human milk are the normative standards for infant feeding and nutrition", and refers to decisions regarding the supply of infant nutrition as "a public health issue and not only a lifestyle choice… [g]iven the documented short- and long-term medical and neurodevelopmental advantages of breastfeeding". The AAP policy recommends breastfeeding exclusively for six months, continuing it with introduction of complementary foods, with an overall duration of "1 year or longer as mutually desired by mother and infant". The body of the policy statement notes and cites literature indicating that, in addition to the importance of mother's milk, the manner of the food delivery has implications: that "breastfed infants self-regulate intake volume", whereas bottle-fed infants receiving expressed breast milk or formula have "increased bottle emptying, poorer self-regulation, and excessive weight gain in late infancy", and that such early practice of self-regulation correlate with adult patterns of weight gain (ibid.). The AAP policy notes that "[m]edical contraindications to breastfeeding are rare". The transmission of some viral diseases through breastfeeding is reportedly preventable, e.g., by expressing breast milk and subjecting it to Holder pasteurization.
A functional beverage is a drink marketed to highlight specific product ingredients or supposed health effects. Beverages marketed as "functional" include dairy drinks, sports and performance drinks, energy drinks, ready-to-drink teas, kombucha, "smart" drinks, fortified fruit drinks, plant milks, and enhanced water. Although these beverages may serve to hydrate a consumer, they have no proven health effects, and accordingly appear not to be "functional". For example, there is no good clinical evidence that kombucha provides any benefit to human health.
Sources: en.wikipedia.org
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.
It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.
Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.